References
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:https://doi.org/10.3322/caac.21262
- Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac J Cancer Prev. 2019;20(7):2015–2020. doi:https://doi.org/10.31557/APJCP.2019.20.7.2015
- Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B. Breast cancer intrinsic subtype classification, clinical use, and future trends. Am. J. Cancer Res. 2015;315(10):2929–2934.
- Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. 2015;6(29):26560–26574. doi:https://doi.org/10.18632/oncotarget.5306
- Reinhardt F, Franken A, Fehm T, Neubauer H. Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: a potential role for Liquid Biopsies? Tumour Biol. 2017;39(11):1–15. doi:https://doi.org/10.1177/1010428317731511
- Sheweita SA, Sheikh BY. Can dietary antioxidants reduce the incidence of brain tumors? Curr Drug Metab. 2011;12(6):587–593. doi:https://doi.org/10.2174/138920011795713733
- Sheweita S, Mashaly S, Newairy AS, Abdou H, Eweda S. Changes in Oxidative stress and antioxidant enzyme activities in streptozotocin-induced diabetes mellitus in rats. Role of Alhagi maurorum extracts. Oxid Med Cellular Long. 2016;1–8.
- Sheweita SA, Al Samghan AS, Khoshhal OK. Osteoporosis in children. possible risk factors and role of antioxidants. J Musculoskelet Surg Res. 2019;3(4):319–325. doi:https://doi.org/10.4103/jmsr.jmsr_40_19
- Sheweita SA, ElHady SA, Hammoda HM. Trigonella stellata reduced the deleterious effects of diabetes mellitus through alleviation of oxidative stress, antioxidant- and drug-metabolizing enzymes activities. J Ethnopharmacol. 2020; 256:112821. (Epub ahead of print) doi:https://doi.org/10.1016/j.jep.2020.112821
- Sultan AS, Marie MA, Sheweita SA. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018;41:34–41. doi:https://doi.org/10.1016/j.breast.2018.06.009
- Kosuru R, Rai U, Prakash S, Singh A, Singh S. Promising therapeutic potential of pterostilbene and its mechanistic insight based on preclinical evidence. Eur J Pharmacol. 2016;789:229–243. doi:https://doi.org/10.1016/j.ejphar.2016.07.046
- McCormack D, McFadden D. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482. doi:https://doi.org/10.1155/2013/575482
- Gómez-Zorita S, Fernández-Quintela A, Aguirre L, Macarulla MT, Rimando AM, Portillo MP. Pterostilbene improves glycaemic control in rats fed an obesogenic diet: involvement of skeletal muscle and liver. Food Funct. 2015;6(6):1968–1976. doi:https://doi.org/10.1039/c5fo00151j
- Pan C, Hu Y, Li J, Wang Z, Huang J, Zhang S, Ding L. Estrogen Receptor-α36 Is Involved in Pterostilbene-Induced Apoptosis and Anti-Proliferation in In vitro and in vivo breast cancer. PLoS One. 2014;9(8):e104459. doi:https://doi.org/10.1371/journal.pone.0104459
- Kostin SF, McDonald DE, McFadden DW. Inhibitory effects of (−)-epigallocatechin-3-gallate and pterostilbene on pancreatic cancer growth in vitro. J. Surg. Res. 2012;177(2):255–262. doi:https://doi.org/10.1016/j.jss.2012.04.023
- Dhar S, Kumar A, Zhang L, Rimando AM, Lage JM, Lewin JR, Atfi A, Zhang X, Levenson AS. Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer. Oncotarget. 2016;7(14):18469–18484. doi:https://doi.org/10.18632/oncotarget.7841
- Sirerol JA, Rodríguez ML, Mena S, Asensi MA, Estrela JM, Ortega AL. Role of natural stilbenes in the prevention of cancer. Oxid Med Cell Longev. 2016;2016:3128951. doi:https://doi.org/10.1155/2016/3128951
- Chen R-J, Wu P-H, Ho C-T, Way T-D, Pan M-H, Chen H-M, Ho Y-S, Wang Y-J. P53-dependent downregulation of hTERT protein expression and telomerase activity induces senescence in lung cancer cells as a result of pterostilbene treatment. Cell Death Dis. 2017;8(8):e2985. doi:https://doi.org/10.1038/cddis.2017.333
- Moon D, McCormack D, McDonald D, McFadden D. Pterostilbene induces mitochondrially derived apoptosis in breast cancer cells in vitro. J Surg Res. 2013;180(2):208–215. doi:https://doi.org/10.1016/j.jss.2012.04.027
- Su C-M, Lee W-H, Wu ATH, Lin Y-K, Wang L-S, Wu C-H, Yeh C-T. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. J Nutr Biochem. 2015;26(6):675–685. doi:https://doi.org/10.1016/j.jnutbio.2015.01.005
- Yoshida K, Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010;101(4):831–835. doi:https://doi.org/10.1111/j.1349-7006.2009.01488.x
- Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death Differ. 2018;25(1):154–160. doi:https://doi.org/10.1038/cdd.2017.180
- Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 2000;14(14):2291–2302. doi:https://doi.org/10.1096/fj.00-0128com
- Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA. 2010;107(1):246–251. doi:https://doi.org/10.1073/pnas.0908428107
- Haupt S, Raghu D, Haupt Y. Mutant p53 drives cancer by subverting multiple tumor suppression pathways. Front Oncol. 2016;6:12. doi:10.3389/fonc.00012. doi:https://doi.org/10.3389/fonc.2016.00012
- Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi M-Y, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP, et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis. 2012;33(2):442–451. doi:https://doi.org/10.1093/carcin/bgr270
- Bae Y-H, Shin J-M, Park H-J, Jang H-O, Bae M-K, Bae S-K. Gain-of-function mutant p53-R280K mediates survival of breast cancer cells. Genes Genom. 2014;36(2):171–178. doi:https://doi.org/10.1007/s13258-013-0154-9
- Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 2009;101(9):1606–1612. doi:https://doi.org/10.1038/sj.bjc.6605335
- Siddiqui JA, Singh A, Chagtoo M, Singh N, Godbole MM, Chakravarti B. Phytochemicals for breast cancer therapy: current status and future implications. Curr Cancer Drug Targets. 2015;15(2):116–135. doi:https://doi.org/10.2174/1568009615666141229152256
- Pan MH, Chang YH, Badmaev V, Nagabhushanam K, Ho CT. Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells. J Agric Food Chem. 2007;55(19):7777–7785. doi:https://doi.org/10.1021/jf071520h
- Guo L, Tan K, Wang H, Zhang X. Pterostilbene inhibits hepatocellular carcinoma through p53/SOD2/ROS-mediated mitochondrial apoptosis. Oncol Rep. 2016;36(6):3233–3240. doi:https://doi.org/10.3892/or.2016.5151
- Hong BH, Wu CH, Yeh CT, Yen GC. Invadopodia-associated proteins blockade as a novel mechanism for 6-shogaol and pterostilbene to reduce breast cancer cell motility and invasion. Mol Nutr Food Res. 2013;57(5):886–895. doi:https://doi.org/10.1002/mnfr.201200715
- Wakimoto R, Ono M, Takeshima M, Higuchi T, Nakano S. Differential anticancer activity of pterostilbene against three subtypes of human breast cancer cells. Anticancer Res. 2017;37(11):6153–6159. doi:https://doi.org/10.21873/anticanres.12064
- Fu Z, Yang J, Wei Y, Li J. Effects of piceatannol and pterostilbene against β-amyloid-induced apoptosis on the PI3K/Akt/Bad signaling pathway in PC12 cells. Food Funct. 2016;7(2):1014–1023. doi:https://doi.org/10.1039/c5fo01124h
- Hung CM, Liu LC, Ho CT, Lin YC, Way TD. Pterostilbene enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistance triple negative breast cancer cells. J Agric Food Chem. 2017;65(51):11179–11191. doi:https://doi.org/10.1021/acs.jafc.7b02358
- Ersoz M, Coskun ZM, Acikgoz B, Karalti I, Cobanoglu G, Cesal C. In vitro evaluation of cytotoxic, anti-proliferative, anti-oxidant, apoptotic, and anti-microbial activities of Cladonia pocillum. Cell Mol Biol (Noisy-le-Grand). 2017;63(7):69–75. doi:https://doi.org/10.14715/cmb/2017.63.7.12
- Li Z, Khaletskiy A, Wang J, Wong JY, Oberley LW, Li JJ. Genes regulated in human breast cancer cells overexpressing manganese-containing superoxide dismutase. Free Rad Biol. 2001;30(3);260–267.
- Koboldt DC, Fulton R, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61–70.
- Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339. doi:https://doi.org/10.1038/nature12634
- Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene. 2007;26(15):2212–2219. doi:https://doi.org/10.1038/sj.onc.1210296
- Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 2013;20(7):898–909. doi:https://doi.org/10.1038/cdd.2013.17
- Mello SS, Attardi LD. Not all p53 gain-of-function mutants are created equal. Cell Death Differ. 2013;20(7):855–857. doi:https://doi.org/10.1038/cdd.2013.53
- Montazeri M, Pilehvar-Soltanahmadi Y, Mohaghegh M, Panahi A, Khodi S, Zarghami N, Sadeghizadeh M. Antiproliferative and apoptotic effects of dendrosomal curcumin nanoformulation in P53 mutant and wide-type cancer cell lines. Anticancer Agents Mec Chem. 2017;17(5);662–673.
- Wang J, Zhao Q, Qi Q, Gu H-y, Rong J-j, Mu R, Zou M-j, Tao L, You Q-d, Guo Q-l, et al. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J Cell Biochem. 2011;112(2):509–519. doi:https://doi.org/10.1002/jcb.22941
- Cagatay T, Ozturk M. p53 mutation as a source of aberrant beta-catenin accumulation in cancer cells . Oncogene. 2002;21(52):7971–7980. doi:https://doi.org/10.1038/sj.onc.1205919
- Yallowitz AR, Li D, Lobko A, Mott D, Nemajerova A, Marchenko N. Mutant p53 amplifies epidermal growth factor receptor family signaling to promote mammary tumorigenesis. Mol Cancer Res. 2015;13(4):743–754. doi:https://doi.org/10.1158/1541-7786.MCR-14-0360
- Grunt TW, Mariani GL. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 2013;13(2):188–204. doi:https://doi.org/10.2174/1568009611313020008
- Cheng T-C, Lai C-S, Chung M-C, Kalyanam N, Majeed M, Ho C-T, Ho Y-S, Pan M-H. Potent anti-cancer effect of 3′-hydroxypterostilbene in human colon xenograft tumors. PLoS One. 2014;9(11):e111814. doi:https://doi.org/10.1371/journal.pone.0111814
- Ko C-P, Lin C-W, Chen M-K, Yang S-F, Chiou H-L, Hsieh M-J. Pterostilbene induce autophagy on human oral cancer cells through modulation of Akt and mitogen-activated protein kinase pathway. Oral Oncol. 2015;51(6):593–601. doi:https://doi.org/10.1016/j.oraloncology.2015.03.007
- Roué G, Pichereau V, Lincet H, Colomer D, Sola B. Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators. Oncogene. 2008;27(36):4909–4920. doi:https://doi.org/10.1038/onc.2008.126
- Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat. 2005;91(2):145–151. doi:https://doi.org/10.1007/s10549-004-6457-4
- Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KLB. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol. 2008;181(1):51–63. doi:https://doi.org/10.1083/jcb.200707018
- Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther. 2008;7(7):1782–1788. doi:https://doi.org/10.1158/1535-7163.MCT-07-2357
- Wang Y, Ding L, Wang X, Zhang J, Han W, Feng L, Sun J, Jin H, Wang XJ. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cytoprotective autophagy in breast cancer cells. Am. J. Transl. Res. 2012;4(1):44.